JPMorgan raises Biogen stock target to USD 300.00 without a date? no

Published on 10/20/2026 at 19:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen stock has results due October 28, 2026 before the open. It costs EUR 217.10 at Lang & Schwarz on October 20, 2026 at 7:02 p.m. CEST.

Analyst view and reporting date

JPMorgan raised its Biogen target from USD 210.00 to USD 300.00 on October 12, 2026.
Biogen is expected to report third-quarter results on October 28, 2026, before the market opens.
Biogen stock costs EUR 217.10 at Lang & Schwarz on October 20, 2026 at 7:02 p.m. CEST.

Aquarell-Panorama der Skyline von Cambridge MA mit Universitäts- und Biotech-Gebäuden am Fluss — Biogen Inc. Heimatstadt Cambridge Massachusetts am Charles River in zarter Aquarell-Illustration ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) remains defined by JPMorgan's October 12, 2026 upgrade from Neutral to Overweight and its target increase from USD 210.00 to USD 300.00, as CNBC reported. At Lang & Schwarz, Biogen stock was trading at EUR 217.10 on October 20, 2026 at 7:02 p.m. CEST.

October 28 brings the next test

Biogen is expected to report its third-quarter 2026 results before the market opens on October 28, 2026, with a conference call scheduled for 8:30 a.m. ET, according to MarketBeat. The same page lists consensus revenue of USD 2.63 billion and consensus earnings per share of USD 1.98 for the quarter.

Nasdaq price stays near the yearly high

Biogen's Nasdaq quote was USD 243.62 at 1:05 p.m. ET on October 20, 2026, while its 52-week range ran from USD 138.00 to USD 244.65. The upper end was USD 1.03 above that quote, placing the stock 0.42 percent below its 52-week high. The company's market capitalization was USD 36.0 billion.

What does the estimate imply?

The consensus revenue forecast of USD 2.63 billion compares with USD 2.53 billion in the year-earlier quarter, while the consensus earnings-per-share forecast of USD 1.98 compares with USD 4.81. MarketBeat also records Biogen's second-quarter 2026 revenue at USD 2.74 billion and earnings per share at USD 3.60, giving the October report a lower earnings hurdle but a higher revenue expectation.

Pipeline expectations shape valuation

JPMorgan's target reflects the firm's view that upcoming clinical readouts could broaden Biogen's growth profile beyond established medicines. CNBC reported that the analyst highlighted felzartamab, litifilimab and further Leqembi-related read-throughs, with litifilimab data from two phase three trials expected in the fourth quarter of 2026.

Stock and earnings in view

For investors, the key near-term comparison is between the USD 300.00 JPMorgan target and the USD 243.62 Nasdaq quote, while the October 28 report will test the USD 2.63 billion revenue expectation.

The stock was trading at EUR 217.10 at Lang & Schwarz on October 20, 2026 at 7:02 p.m. CEST, and the latest Nasdaq quote was USD 243.62 at 1:05 p.m. ET on the same date. The further course of trading is shown by the continuously updated real-time quote of Biogen stock.